Mural Oncology’s (MURA) Hold Rating Reiterated at Jones Trading

Jones Trading reaffirmed their hold rating on shares of Mural Oncology (NASDAQ:MURA) in a report issued on Tuesday, MarketBeat Ratings reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Mural Oncology in a report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $13.00.

Mural Oncology Price Performance

Shares of Mural Oncology stock opened at $1.35 on Tuesday. Mural Oncology has a 1 year low of $1.28 and a 1 year high of $5.12. The stock has a market cap of $23.26 million, a PE ratio of -0.15 and a beta of 3.66. The firm has a fifty day moving average price of $3.77 and a 200 day moving average price of $3.58.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period in the previous year, the firm posted ($3.57) earnings per share. As a group, equities analysts expect that Mural Oncology will post -7.54 EPS for the current year.

Hedge Funds Weigh In On Mural Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MURA. Commerce Bank purchased a new position in Mural Oncology in the 3rd quarter valued at about $39,000. FMR LLC lifted its position in shares of Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after acquiring an additional 11,423 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Mural Oncology in the third quarter worth approximately $340,000. Geode Capital Management LLC boosted its stake in shares of Mural Oncology by 2.6% in the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after acquiring an additional 4,731 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Mural Oncology during the fourth quarter worth approximately $181,000. 80.21% of the stock is owned by hedge funds and other institutional investors.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.